LLY

1,030.68

+0.87%↑

JNJ

200.1

+0.41%↑

ABBV

233.97

+0.04%↑

UNH

313.81

-2.05%↓

AZN

89.31

+0.18%↑

LLY

1,030.68

+0.87%↑

JNJ

200.1

+0.41%↑

ABBV

233.97

+0.04%↑

UNH

313.81

-2.05%↓

AZN

89.31

+0.18%↑

LLY

1,030.68

+0.87%↑

JNJ

200.1

+0.41%↑

ABBV

233.97

+0.04%↑

UNH

313.81

-2.05%↓

AZN

89.31

+0.18%↑

LLY

1,030.68

+0.87%↑

JNJ

200.1

+0.41%↑

ABBV

233.97

+0.04%↑

UNH

313.81

-2.05%↓

AZN

89.31

+0.18%↑

LLY

1,030.68

+0.87%↑

JNJ

200.1

+0.41%↑

ABBV

233.97

+0.04%↑

UNH

313.81

-2.05%↓

AZN

89.31

+0.18%↑

Search

Edwards Lifesciences Corp

Gesloten

SectorGezondheidszorg

84.06 -0.78

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

83.96

Max

85.6

Belangrijke statistieken

By Trading Economics

Inkomsten

-41M

290M

Verkoop

21M

1.6B

K/W

Sectorgemiddelde

36.877

105.69

Winstmarge

18.692

Werknemers

15,800

EBITDA

-52M

348M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+9.69% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.3B

49B

Vorige openingsprijs

84.84

Vorige sluitingsprijs

84.06

Nieuwssentiment

By Acuity

22%

78%

44 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Edwards Lifesciences Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 aug 2025, 18:44 UTC

Acquisities, Fusies, Overnames

FTC Files Lawsuit to Block Edwards Lifesciences' Purchase of JenaValve Technology

Peer Vergelijking

Prijswijziging

Edwards Lifesciences Corp Prognose

Koersdoel

By TipRanks

9.69% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 92.95 USD  9.69%

Hoogste 104 USD

Laagste 83 USD

Gebaseerd op 24 Wall Street-analisten die 12-maands prijsdoelen bieden voor Edwards Lifesciences Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

24 ratings

14

Buy

10

Hold

0

Sell

Technische score

By Trading Central

74.52 / 75.54Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Strong Bullish Evidence

Sentiment

By Acuity

44 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
help-icon Live chat